Scientists test new way to spot Cancer-Fighting immune cells in lymph nodes
NCT ID NCT02831634
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested a method to identify tumor mutations and measure immune cell responses in the lymph nodes of 25 patients with breast cancer or melanoma. Researchers took blood samples and used two techniques to find which mutations trigger T-cell activity. The goal was to see if this approach is feasible for future personalized cancer treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie
Paris, 75005, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this method could help develop personalized cancer vaccines or immunotherapies by identifying which tumor mutations trigger an immune response.
What could go wrong
This is a very early feasibility study with only 25 participants. The method may not work in all patients or may be too complex for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.